MRC1 and neoplasm: As shown in Fig. 6H–J, PB@MC treatment significantly ameliorated CD4+ and CD8+ production, enhanced CD3 expression, and reduced CD206 expression in tumour sections, indicating the activation of T cells and reduced M2-like macrophage infiltration within the tumour microenvironment31,32.